Soleus Capital Management, L.P. Eiger Bio Pharmaceuticals, Inc. Transaction History

Soleus Capital Management, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$6.04 - $9.66 $3.79 Million - $6.06 Million	-627,000 Reduced 74.11%	219,000 $1.65 Million
Q2 2022 Aug 15, 2022	BUY	$4.99 - $8.96 $314,370 - $564,480	63,000 Added 8.05%	846,000 $5.33 Million
Q1 2022 May 16, 2022	BUY	$3.84 - $9.74 $3.01 Million - $7.63 Million	783,000 New	783,000 $6.5 Million
Q4 2021 Feb 14, 2022	SELL	$5.12 - $8.19 $1.09 Million - $1.75 Million	-213,519 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$8.44 - $12.66 $234,632 - $351,948	27,800 Added 14.97%	213,519 $1.89 Million
Q4 2020 Feb 16, 2021	SELL	$7.98 - $12.29 $2.29 Million - $3.53 Million	-286,839 Reduced 60.7%	185,719 $2.28 Million
Q3 2020 Nov 13, 2020	SELL	$7.96 - $12.42 $1.18 Million - $1.83 Million	-147,708 Reduced 23.81%	472,558 $3.85 Million
Q2 2020 Aug 14, 2020	BUY	$5.4 - $13.37 $1.16 Million - $2.88 Million	215,059 Added 53.07%	620,266 $5.95 Million
Q1 2020 May 15, 2020	BUY	$4.91 - $14.7 $981,018 - $2.94 Million	199,800 Added 97.27%	405,207 $2.76 Million
Q4 2019 Feb 14, 2020	BUY	$9.77 - $15.66 $2.01 Million - $3.22 Million	205,407 New	205,407 $3.06 Million

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $418M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Soleus Capital Management, L.P. with notifications on news.